Transforming Large B-Cell Lymphoma (LBCL): CAR T and Novel Agents - Episode 7

Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents

December 5, 2023

Fred Locke, MD, provides an overview of transplant eligibility for patients with large B-cell lymphoma, highlighting second line strategies with CAR T-cell therapy and bispecific antibodies.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Understanding LBCL: Presentation, Diagnosis, and Prognostic Indicators

EP. 2: Large B-Cell Lymphoma: Treatment Approaches and Evolving Therapies

EP. 3: Advancing Lymphoma Treatments: CAR T-Cell and Bispecific Therapies

EP. 4: CAR T-Cell Therapy’s Impact on Lymphoma Management

EP. 5: Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma

EP. 6: Challenges in CAR T-Cell Therapy for Lymphoma

Now Viewing

EP. 7: Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents

EP. 8: CAR T: A Review of Clinical Data for Second Line Treatments of Large B-Cell Lymphoma

EP. 9: Approaches to Treatment Sequencing in LBCL

EP. 10: Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and Bispecifics

EP. 11: ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL

EP. 12: Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL

EP. 13: Observations in Progression Post-CAR T for Lymphoma

EP. 14: Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

EP. 15: Future Perspectives in Large B-Cell Lymphoma